Brooktree Capital Management Has $6.29 Million Position in Pfizer Inc. (NYSE:PFE)

Brooktree Capital Management raised its holdings in shares of Pfizer Inc. (NYSE:PFEGet Rating) by 7.5% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 121,545 shares of the biopharmaceutical company’s stock after purchasing an additional 8,432 shares during the period. Pfizer comprises about 4.1% of Brooktree Capital Management’s portfolio, making the stock its 9th largest holding. Brooktree Capital Management’s holdings in Pfizer were worth $6,292,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in PFE. BerganKDV Wealth Management LLC grew its position in shares of Pfizer by 7.3% during the first quarter. BerganKDV Wealth Management LLC now owns 65,099 shares of the biopharmaceutical company’s stock worth $3,370,000 after acquiring an additional 4,434 shares during the last quarter. Avantax Planning Partners Inc. grew its position in shares of Pfizer by 19.4% during the first quarter. Avantax Planning Partners Inc. now owns 119,151 shares of the biopharmaceutical company’s stock worth $6,168,000 after acquiring an additional 19,370 shares during the last quarter. Beaumont Financial Partners LLC grew its position in shares of Pfizer by 11.6% during the first quarter. Beaumont Financial Partners LLC now owns 29,186 shares of the biopharmaceutical company’s stock worth $1,511,000 after acquiring an additional 3,041 shares during the last quarter. Cypress Capital LLC grew its position in shares of Pfizer by 4.6% during the first quarter. Cypress Capital LLC now owns 43,339 shares of the biopharmaceutical company’s stock worth $2,244,000 after acquiring an additional 1,902 shares during the last quarter. Finally, Fort Sheridan Advisors LLC grew its position in shares of Pfizer by 1.9% during the first quarter. Fort Sheridan Advisors LLC now owns 80,014 shares of the biopharmaceutical company’s stock worth $4,142,000 after acquiring an additional 1,492 shares during the last quarter. Institutional investors own 66.50% of the company’s stock.

Insider Buying and Selling

In related news, SVP Jennifer B. Damico sold 4,000 shares of the stock in a transaction that occurred on Monday, May 16th. The stock was sold at an average price of $50.50, for a total value of $202,000.00. Following the transaction, the senior vice president now owns 15,064 shares in the company, valued at $760,732. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In other Pfizer news, SVP Jennifer B. Damico sold 4,000 shares of the stock in a transaction that occurred on Monday, May 16th. The stock was sold at an average price of $50.50, for a total transaction of $202,000.00. Following the transaction, the senior vice president now owns 15,064 shares in the company, valued at $760,732. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, SVP Jennifer B. Damico sold 4,218 shares of the stock in a transaction that occurred on Tuesday, June 7th. The shares were sold at an average price of $53.96, for a total value of $227,603.28. Following the transaction, the senior vice president now owns 10,846 shares in the company, valued at approximately $585,250.16. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 41,126 shares of company stock worth $2,075,003. Insiders own 0.05% of the company’s stock.

Pfizer Stock Down 1.2 %

Shares of PFE traded down $0.59 during trading hours on Friday, reaching $49.27. The company’s stock had a trading volume of 16,376,601 shares, compared to its average volume of 16,878,314. The firm has a market cap of $276.45 billion, a price-to-earnings ratio of 9.64, a P/E/G ratio of 0.61 and a beta of 0.67. Pfizer Inc. has a 1-year low of $40.94 and a 1-year high of $61.71. The company has a quick ratio of 1.13, a current ratio of 1.39 and a debt-to-equity ratio of 0.43. The company has a 50 day moving average of $51.09 and a two-hundred day moving average of $51.10.

Pfizer (NYSE:PFEGet Rating) last issued its earnings results on Thursday, July 28th. The biopharmaceutical company reported $2.04 earnings per share for the quarter, beating analysts’ consensus estimates of $1.95 by $0.09. Pfizer had a return on equity of 44.38% and a net margin of 28.92%. The company had revenue of $27.74 billion for the quarter, compared to the consensus estimate of $26.20 billion. During the same quarter in the prior year, the company earned $1.07 EPS. The firm’s quarterly revenue was up 46.8% on a year-over-year basis. As a group, research analysts predict that Pfizer Inc. will post 6.54 EPS for the current fiscal year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 6th. Investors of record on Wednesday, June 29th will be issued a $0.40 dividend. The ex-dividend date of this dividend is Thursday, July 28th. This represents a $1.60 dividend on an annualized basis and a yield of 3.25%. Pfizer’s dividend payout ratio is currently 31.31%.

Analyst Ratings Changes

PFE has been the subject of several research analyst reports. Barclays upped their price objective on shares of Pfizer from $50.00 to $52.00 and gave the stock an “equal weight” rating in a report on Monday, August 1st. Morgan Stanley reduced their price objective on shares of Pfizer from $52.00 to $49.00 and set an “equal weight” rating for the company in a report on Friday, July 8th. StockNews.com raised shares of Pfizer from a “buy” rating to a “strong-buy” rating in a report on Tuesday, April 19th. SVB Leerink reduced their price objective on shares of Pfizer from $55.00 to $53.00 and set a “market perform” rating for the company in a report on Friday, July 29th. Finally, JPMorgan Chase & Co. set a $57.00 price target on shares of Pfizer in a report on Tuesday, June 28th. Nine analysts have rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $57.50.

Pfizer Profile

(Get Rating)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.

Read More

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.